Jasper Therapeutics (NASDAQ:JSPR) Earns “Buy” Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR – Free Report) in a research note released on Tuesday,Benzinga reports. They currently have a $40.00 price target on the stock. A number of other research firms have also issued reports on JSPR. UBS Group initiated coverage on shares of Jasper Therapeutics in […]
HC Wainwright restated their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR – Free Report) in a research note released on Tuesday,Benzinga reports. They currently have a $40.00 price target on the stock. A number of other research firms have also issued reports on JSPR. UBS Group initiated coverage on shares of Jasper Therapeutics in […]
